company background image
LOGC logo

LogicBio Therapeutics NasdaqGM:LOGC Stock Report

Last Price

US$2.07

Market Cap

US$68.2m

7D

0.5%

1Y

-40.3%

Updated

16 Nov, 2022

Data

Company Financials +

LogicBio Therapeutics, Inc.

NasdaqGM:LOGC Stock Report

Market Cap: US$68.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

LOGC Stock Overview

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. More details

LOGC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

LogicBio Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for LogicBio Therapeutics
Historical stock prices
Current Share PriceUS$2.07
52 Week HighUS$3.63
52 Week LowUS$0.26
Beta4.62
1 Month Change0.98%
3 Month Change417.63%
1 Year Change-40.35%
3 Year Change-76.79%
5 Year Changen/a
Change since IPO-82.00%

Recent News & Updates

Recent updates

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

Oct 03

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

Aug 20
Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 18
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

LogicBio GAAP EPS of -$0.15, revenue of $3.2M

Aug 15

Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Jan 11
Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Aug 18
Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Apr 12
Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

Mar 08
Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

Jan 15
The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

Shareholder Returns

LOGCUS BiotechsUS Market
7D0.5%-6.1%1.3%
1Y-40.3%-13.2%8.2%

Return vs Industry: LOGC underperformed the US Biotechs industry which returned -15.1% over the past year.

Return vs Market: LOGC underperformed the US Market which returned -21.9% over the past year.

Price Volatility

Is LOGC's price volatile compared to industry and market?
LOGC volatility
LOGC Average Weekly Movement179.9%
Biotechs Industry Average Movement11.9%
Market Average Movement7.9%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market4.1%

Stable Share Price: LOGC's share price has been volatile over the past 3 months.

Volatility Over Time: LOGC's weekly volatility has increased from 92% to 180% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201462Fred Chereauwww.logicbio.com

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company’s GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.

LogicBio Therapeutics, Inc. Fundamentals Summary

How do LogicBio Therapeutics's earnings and revenue compare to its market cap?
LOGC fundamental statistics
Market capUS$68.23m
Earnings (TTM)-US$26.54m
Revenue (TTM)US$10.76m

6.3x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LOGC income statement (TTM)
RevenueUS$10.76m
Cost of RevenueUS$30.68m
Gross Profit-US$19.92m
Other ExpensesUS$6.62m
Earnings-US$26.54m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.81
Gross Margin-185.15%
Net Profit Margin-246.71%
Debt/Equity Ratio37.7%

How did LOGC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/16 12:09
End of Day Share Price 2022/11/15 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LogicBio Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Gbolahan Amusa BenzChardan Capital Markets, LLC
Silvan TuerkcanCitizens JMP Securities, LLC